{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T13:50:40Z","timestamp":1783691440340,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001511","name":"Auckland Medical Research Foundation","doi-asserted-by":"publisher","award":["2116013"],"award-info":[{"award-number":["2116013"]}],"id":[{"id":"10.13039\/501100001511","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016905","name":"Hugh Green Foundation","doi-asserted-by":"publisher","award":["3712033"],"award-info":[{"award-number":["3712033"]}],"id":[{"id":"10.13039\/100016905","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","pathologyjournal.rcpa.edu.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.pathol.2021.10.002","type":"journal-article","created":{"date-parts":[[2022,1,23]],"date-time":"2022-01-23T20:00:52Z","timestamp":1642968052000},"page":"417-424","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Tumour infiltrating lymphocyte density differs by meningioma type and is associated with prognosis in atypical meningioma"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2138-7633","authenticated-orcid":false,"given":"Clinton P.","family":"Turner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4106-1435","authenticated-orcid":false,"given":"Jessica","family":"McLay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7584-887X","authenticated-orcid":false,"given":"Ian F.","family":"Hermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Correia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold","family":"Bok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasim","family":"Mehrabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Gock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5171-7998","authenticated-orcid":false,"given":"Blake","family":"Highet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice A.","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1711-1631","authenticated-orcid":false,"given":"Michael","family":"Dragunow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pathol.2021.10.002_bib1","series-title":"World Health Organization Histological Classification of Tumours of the Central Nervous System","author":"Louis","year":"2016"},{"issue":"Suppl 1","key":"10.1016\/j.pathol.2021.10.002_bib2","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/noaa200","article-title":"CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013\u20132017","volume":"30","author":"Ostrom","year":"2020","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.pathol.2021.10.002_bib3","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.jocn.2020.06.011","article-title":"The epidemiology of patients undergoing meningioma resection in Auckland, New Zealand, 2002 to 2011","volume":"80","author":"Turner","year":"2020","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.pathol.2021.10.002_bib4","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1097\/00000478-199712000-00008","article-title":"Meningioma grading: an analysis of histologic parameters","volume":"21","author":"Perry","year":"1997","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.pathol.2021.10.002_bib5","first-page":"2046","article-title":"\u201cMalignancy\u201d in meningiomas","volume":"85","author":"Perry","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.pathol.2021.10.002_bib6","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/bpa.12174","article-title":"Mitotic index is an independent predictor of recurrence-free survival in meningioma: mitotic index in meningioma","volume":"25","author":"Olar","year":"2015","journal-title":"Brain Pathol"},{"key":"10.1016\/j.pathol.2021.10.002_bib7","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/ni.2703","article-title":"Innate and adaptive immune cells in the tumor microenvironment","volume":"14","author":"Gajewski","year":"2013","journal-title":"Nat Immunol"},{"key":"10.1016\/j.pathol.2021.10.002_bib8","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1200\/JCO.2011.37.8539","article-title":"Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma","volume":"30","author":"Azimi","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pathol.2021.10.002_bib9","doi-asserted-by":"crossref","first-page":"5944","DOI":"10.1200\/JCO.2008.19.6147","article-title":"In situ cytotoxic and memory t cells predict outcome in patients with early-stage colorectal cancer","volume":"27","author":"Pag\u00e8s","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pathol.2021.10.002_bib10","series-title":"Invasive Melanoma, Histopathology Reporting Guide","author":"Scolyer","year":"2019"},{"key":"10.1016\/j.pathol.2021.10.002_bib11","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(18)30789-X","article-title":"International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study","volume":"391","author":"Pag\u00e8s","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.pathol.2021.10.002_bib12","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1038\/bjc.2014.162","article-title":"Tumour-infiltrating CD4+ and CD8+ lymphocytes as predictors of clinical outcome in glioma","volume":"110","author":"Han","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.pathol.2021.10.002_bib13","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1126\/science.1079490","article-title":"Control of regulatory T cell development by the transcription factor Foxp3","volume":"299","author":"Hori","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.pathol.2021.10.002_bib14","doi-asserted-by":"crossref","first-page":"e111757","DOI":"10.1371\/journal.pone.0111757","article-title":"Analysis of FoxP3+ T-regulatory cells and CD8+ T-cells in ovarian carcinoma: location and tumor infiltration patterns are key prognostic markers","volume":"9","author":"Hermans","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.pathol.2021.10.002_bib15","doi-asserted-by":"crossref","first-page":"15179","DOI":"10.1038\/srep15179","article-title":"Prognostic value of tumor-infiltrating FoxP3 + regulatory T cells in cancers: a systematic review and meta-analysis","volume":"5","author":"Shang","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.pathol.2021.10.002_bib16","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00262-014-1519-x","article-title":"PD-1(+) immune cell infiltration inversely correlates with survival of operable breast cancer patients","volume":"63","author":"Sun","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.pathol.2021.10.002_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0082870","article-title":"Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas","volume":"8","author":"Kim","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pathol.2021.10.002_bib18","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/j.ajpath.2012.07.033","article-title":"Immunophenotypic identification and characterization of tumor cells and infiltrating cell populations in meningiomas","volume":"181","author":"Domingues","year":"2012","journal-title":"Am J Pathol"},{"key":"10.1016\/j.pathol.2021.10.002_bib19","first-page":"1479","article-title":"The immune cell infiltrate populating meningiomas is composed of mature, antigen-experienced T and B cells","volume":"15","author":"Fang","year":"2013","journal-title":"J Neurooncology"},{"key":"10.1016\/j.pathol.2021.10.002_bib20","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s11060-013-1208-1","article-title":"Evaluation of mast cells and hypoxia inducible factor-1 expression in meningiomas of various grades in correlation with peritumoral brain edema","volume":"115","author":"Reszec","year":"2013","journal-title":"J Neurooncol"},{"key":"10.1016\/j.pathol.2021.10.002_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0074798","article-title":"Association between inflammatory infiltrates and isolated mosonomy 22\/del(22q) in meningiomas","volume":"8","author":"Domingues","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pathol.2021.10.002_bib22","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00262-020-02671-z","article-title":"NF2 mutation status and tumor mutational burden correlate with immune cell infiltration in meningiomas","volume":"70","author":"Rutland","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.pathol.2021.10.002_bib23","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.18632\/oncotarget.3082","article-title":"Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma","volume":"6","author":"Du","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.pathol.2021.10.002_bib24","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00262-019-02342-8","article-title":"Systemic and local immunosuppression in patients with high-grade meningiomas","volume":"68","author":"Li","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.pathol.2021.10.002_bib26","series-title":"Ministry of Health, New Zealand. HISO 10001 2017: Ethnicity Data Protocols","year":"2021"},{"key":"10.1016\/j.pathol.2021.10.002_bib27","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1136\/jnnp.20.1.22","article-title":"The recurrence of intracranial meningiomas after surgical treatment","volume":"20","author":"Simpson","year":"1957","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.pathol.2021.10.002_bib28","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1038\/s41596-021-00503-7","article-title":"Preparation, construction and high-throughput automated analysis of human brain tissue microarrays for neurodegenerative disease drug development","volume":"16","author":"Singh-Bains","year":"2021","journal-title":"Nat Protoc"},{"key":"10.1016\/j.pathol.2021.10.002_bib29","doi-asserted-by":"crossref","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.pathol.2021.10.002_bib30","series-title":"The R Project for Statistical Computing. Cited Jul","year":"2021"},{"key":"10.1016\/j.pathol.2021.10.002_bib32","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S1470-2045(17)30155-9","article-title":"DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis","volume":"18","author":"Sahm","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pathol.2021.10.002_bib33","doi-asserted-by":"crossref","first-page":"djv377","DOI":"10.1093\/jnci\/djv377","article-title":"TERT promoter mutations and risk of recurrence in meningioma","volume":"108","author":"Sahm","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.pathol.2021.10.002_bib34","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00401-020-02188-w","article-title":"CDKN2A\/B homozygous deletion is associated with early recurrence in meningiomas","volume":"140","author":"Sievers","year":"2020","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.pathol.2021.10.002_bib35","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00401-018-1899-7","article-title":"DMD genomic deletions characterize a subset of progressive\/higher-grade meningiomas with poor outcome","volume":"136","author":"Juratli","year":"2018","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.pathol.2021.10.002_bib36","doi-asserted-by":"crossref","first-page":"4155","DOI":"10.1158\/1078-0432.CCR-10-0891","article-title":"Genomic profiling reveals alternative genetic pathways of meningioma malignant progression dependent on the underlying NF2 status","volume":"16","author":"Goutagny","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pathol.2021.10.002_bib37","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1097\/00000478-200007000-00001","article-title":"Chordoid meningioma: a clinicopathologic study of 42 cases","volume":"24","author":"Couce","year":"2000","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.pathol.2021.10.002_bib38","series-title":"An open-label phase II study of nivolumab in adult participants with recurrent high-grade meningioma. clinicaltrials.gov;","author":"Reardon","year":"2021"},{"key":"10.1016\/j.pathol.2021.10.002_bib39","series-title":"A phase I\/II study of nivolumab plus or minus ipilimumab in combination with multi-fraction stereotactic radiosurgery for recurrent high-grade radiation-relapsed meningioma","year":"2021"},{"key":"10.1016\/j.pathol.2021.10.002_bib40","series-title":"Phase II trial of the immune checkpoint inhibitor nivolumab in patients with recurrent select rare CNS cancers","year":"2021"},{"key":"10.1016\/j.pathol.2021.10.002_bib41","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.pathol.2021.10.002_bib42","doi-asserted-by":"crossref","first-page":"5260","DOI":"10.1158\/1078-0432.CCR-19-0389","article-title":"Cytotoxic T cells and their activation status are independent prognostic markers in meningiomas","volume":"25","author":"Rapp","year":"2019","journal-title":"Clin Cancer Res"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302521005419?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302521005419?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T21:48:42Z","timestamp":1653860922000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031302521005419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S0031302521005419"],"URL":"https:\/\/doi.org\/10.1016\/j.pathol.2021.10.002","relation":{},"ISSN":["0031-3025"],"issn-type":[{"value":"0031-3025","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumour infiltrating lymphocyte density differs by meningioma type and is associated with prognosis in atypical meningioma","name":"articletitle","label":"Article Title"},{"value":"Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pathol.2021.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}